Skip to main content
← All trials
Advanced Solid TumorFirst-in-humanDrugPhase 1

What this study is

This is an open-label, multicenter, first-in-human dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BGB-58067 alone, in combination with BG-89894 (discontinued), in combination with standard of care therapy, and in combination with novel anticancer therapies in participants with advanced solid tumors and with methylthioadenosine phosphorylase (MTAP) deficiency.

What's being tested

  • BGB-58067

    Intervention · DRUG

  • BG-89894

    Intervention · DRUG

  • Standard of Care Therapy

    Intervention · DRUG

    Administered in accordance with relevant local guidelines and/or prescribing information.

  • RAS(ON) Inhibitors

    Intervention · DRUG

All of BGB-58067, BG-89894, RAS(ON) Inhibitors

Planned doses administered on specified days per protocol.

Study details

Official title
A Phase 1a/b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of PRMT5 Inhibitor BGB-58067 Alone and in Combination With Anticancer Agents in Patients With Advanced Solid Tumors
Sponsor
BeOne Medicines
Conditions
Advanced Solid Tumor
Enrolling
695 people
Starts
2025-01-10
Est. completion
2028-08-31
Design
Open-label, non-randomized, sequential groups, Phase 1
Record
View on ClinicalTrials.gov ↗